Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INCY.MX
Strong BuyIncyte Corporation · Healthcare · United States · $25.3B · Avg Vol: $43K/d
100
StockRankGet insider-trade alerts
Q
90
V
65
M
86
P/E (TTM)
15.9x
ROE
30.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.8B | 62.9B | 72.2B | 87.5B | 14.8% | 99.1B | 101.2B | 106.7B | 10.4% |
| EPS (MXN) | 26.05 | 45.46 | 2.72 | 112.21 | 62.7% | 133.29 | — | — | — |
| Shares | 222.7M | 224.3M | 193.4M | 198.5M | -10.9% | 202.7M | — | — | — |
| Debt | 705.9M | 652.0M | 741.5M | 688.1M | -0.8% | 651.6M | — | — | — |
| Equity | 74.4B | 88.4B | 58.7B | 88.0B | 5.7% | — | — | — | — |
| Op CF | 16.5B | 8.5B | 5.7B | 24.1B | 13.4% | 33.7B | — | — | — |
| Inv CF | -1.3B | -3.5B | 2.7B | -1.7B | — | — | — | — | — |
| Fin CF | -13.5M | -341.1M | -34.4B | 1.7B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.7%
SMA 50SMA 200
Close
$124.65
52W High
$124.65
From 52W High
1.0%
SCORE BREAKDOWN
Quality
90
ROIC
36.2%97.7
ROE
30.7%94.5
GP/Assets
46.6%84.4
Op. Margin
41.9%96.7
FCF/Assets
27.6%97.9
Piotroski
784.0
Int. Cover
50.0x89.3
D/E Ratio
0.01x87.5
Current Ratio
4.59x68.7
Value
65
P/E (TTM)
15.9x70.3
EV/EBITDA
12.9x55.8
P/FCF
13.2x76.1
P/B
0.2x99.5
P/S
4.3x46.8
Div Yield
—N/A
Momentum
86
52W High %
100%99.9
RS 6M
30%85.0
SMA 50/200
1.08x75.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
45%72.3
FUNDAMENTALS
Market Cap
$25.3B
P/E (Forward)
—
Gross Margin
55.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCY.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCY.MX | Incyte Corporation(you) | $25.3B | 100 | Strong Buy |
| EXEL | Exelixis, Inc. | $13.5B | 99 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| RPRXN.MX | Royalty Pharma plc | $35.6B | 77 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 79 | Buy |
| REGN.MX | Regeneron Pharmaceuticals, Inc. | $84.7B | 88 | Strong Buy |
| VRTX.MX | Vertex Pharmaceuticals Incorporated | $138.7B | 94 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.3B | 74 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 73 | Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
Peer medians: ROE -25.0% · P/E 31.1x · Gross margin 58.8%